Exploratory investigation of eight circulating plasma markers in brain tumor patients

Neurosurgical Review

Volumn 36, Issue 1, 2013, Pages 45-56

  Ilhan Mutlu, Aysegul ^a   Wagner, Ludwig ^a   Widhalm, Georg ^a   Wöhrer, Adelheid ^a,b   Bartsch, Sophie ^a   Czech, Thomas ^a   Heinzl, Harald ^a   Leutmezer, Fritz ^a   Prayer, Daniela ^a   Marosi, Christine ^a   Base, Wolfgang ^a   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker; Glioma; Meningioma; Metastasis; Plasma

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 8; NEUROPEPTIDE; NEUROPEPTIDE Y; PLACENTAL GROWTH FACTOR; PROTEIN S100B; SECRETAGOGIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN METASTASIS; BRAIN SURGERY; BRAIN TUMOR; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NEUROPATHOLOGY; NEURORADIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEREOTACTIC RADIOSURGERY;

EID: 84872359755     PISSN: 03445607     EISSN: 14372320     Source Type: Journal    
DOI: 10.1007/s10143-012-0401-6     Document Type: Article

References (47)

1. Attems J, Preusser M, Grosinger-Quass M, Wagner L, Lintner F, Jellinger K (2008) Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease. Neuropathol Appl Neurobiol 34:23-32
2. Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC (2008) Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 112:1726-1732
3. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823
4. Benarroch EE (2009) Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. Neurology 72:1016-1020
5. Bender R, Lange S (2001) Adjusting for multiple testing - when and how? J Clin Epidemiol 54:343-349
6. Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B (2002) Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 13:1430-1437
7. Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7:122-133
8. Brochez L, Naeyaert JM (2000) Serological markers for melanoma. Br J Dermatol 143:256-268
9. Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V (2007) Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 116:380-384
10. Christensen JG, Vincent PW, Klohs WD, Fry DW, Leopold WR, Elliott WL (2005) Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. Mol Cancer Ther 4:938-947
11. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F (1984) Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 8:225-235
12. Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25:1439-1451
13. Englund AT, Geffner ME, Nagel RA, Lippe BM, Braunstein GD (1991) Pediatric germ cell and human chorionic gonadotropin-producing tumors. Clinical and laboratory features. Am J Dis Child 145:1294-1297
14. Frota ER, Rodrigues DH, Donadi EA, Brum DG, Maciel DR, Teixeira AL (2009) Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 460:130-132
15. Gartner W, Ilhan A, Neziri D, Base W, Weissel M, Wohrer A, Heinzl H, Waldhor T, Wagner L, Preusser M (2010) Elevated blood markers 1 year before manifestation of malignant glioma. Neuro Oncol 12:1004-1008
16. Gartner W, Lang W, Leutmetzer F, Domanovits H, Waldhausl W, Wagner L (2001) Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex 11:1161-1169
17. Hamaya K, Doi K, Tanaka T, Nishimoto A (1985) The determination of glial fibrillary acidic protein for the diagnosis and histogenetic study of central nervous system tumors: a study of 152 cases. Acta Med Okayama 39:453-462
18. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 56:559-564
19. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387
20. Hosmer DW, Lemeshow S (2000) Applied logistic regression. Wiley, New York
21. Hu Y, Wang YD, Guo T, Wei WN, Sun CY, Zhang L, Huang J (2007) Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma. Cancer Genet Cytogenet 178:1-10
22. Ilyin SE, Gayle D, Gonzalez-Gomez I, Miele ME, Plata-Salaman CR (1999) Brain tumor development in rats is associated with changes in central nervous system cytokine and neuropeptide systems. Brain Res Bull 48:363-373
23. Jacque CM, Vinner C, Kujas M, Raoul M, Racadot J, Baumann NA (1978) Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J Neurol Sci 35:147-155
24. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336-3341
25. Korner M, Reubi JC (2008) Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors. J Neuropathol Exp Neurol 67:741-749
26. Kos K, Harte AL, James S, Snead DR, O'Hare JP, McTernan PG, Kumar S (2007) Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. Am J Physiol Endocrinol Metab 293:E1335-1340
27. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J (1996) The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27:1304-1305
28. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
29. Lee YB, Nagai A, Kim SU (2002) Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 69:94-103
30. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132
31. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. IARC, Lyon
32. Mariani L, Miceli R, Michilin S, Gion M (2009) Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 14:130-136
33. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD (2004) Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119:174-186
34. Nomura M, Yamagishi S, Harada S, Yamashima T, Yamashita J, Yamamoto H (1998) Placenta growth factor (PlGF) mRNA expression in brain tumors. J Neurooncol 40:123-130
35. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500
36. Pipp I, Wagner L, Rossler K, Budka H, Preusser M (2007) Secretagogin expression in tumours of the human brain and its coverings. APMIS 115:319-326
37. Przedborski S, Goldman S, Schiffmann SN, Vierendeels G, Depierreux M, Levivier M, Hildebrand J, Vanderhaeghen JJ (1988) Neuropeptide Y, somatostatin, and cholecystokinin neurone preservation in anaplastic astrocytomas. Acta Neuropathol 76:507-510
38. Rickmann M, Wolff JR (1995) Modifications of S100-protein immunoreactivity in rat brain induced by tissue preparation. Histochem Cell Biol 103:135-145
39. Saavedra A, Baltazar G, Duarte EP (2008) Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 86:186-215
40. Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T (2009) Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. J Alzheimers Dis 18:331-337
41. Tjwa M, Luttun A, Autiero M, Carmeliet P (2003) VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 314:5-14
42. Vogelbaum MA, Masaryk T, Mazzone P, Mekhail T, Fazio V, McCartney S, Marchi N, Kanner A, Janigro D (2005) S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer 104:817-824
43. +-binding protein. J Biol Chem 275:24740-24751
44. Wiesenhofer B, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C (2000) Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol 99:131-137
45. Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rossler K, Hainfellner JA (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95:401-411
46. Yamamoto H, Gurney ME (1990) Human platelets contain brain-derived neurotrophic factor. J Neurosci 10:3469-3478
47. Yan Q, Yu HL, Li JT (2009) Study on the expression of BDNF in human gliomas. Sichuan Da Xue Xue Bao Yi Xue Ban 40:415-417